Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 20/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22092262 | 1.00 | HCRTR2 (0.58) | HCRTR2 | |
| SCHEMBL31179754 | 1.00 | HCRTR2 (0.58) | HCRTR2 | |
| SCHEMBL24214615 | 0.91 | HCRTR2 (0.47) | HCRTR2 | |
| SCHEMBL23922973 | 0.91 | HCRTR2 (0.47) | HCRTR2 | |
| SCHEMBL23922958 | 0.91 | HCRTR2 (0.56) | HCRTR2 | |
| SCHEMBL30533892 | 0.91 | HCRTR2 (0.56) | HCRTR2 | |
| SCHEMBL24214540 | 0.91 | HCRTR2 (0.56) | HCRTR2 | |
| SCHEMBL24214520 | 0.90 | HCRTR2 (0.60) | HCRTR2 | |
| SCHEMBL23923095 | 0.90 | HCRTR2 (0.60) | HCRTR2 | |
| SCHEMBL24214268 | 0.90 | HCRTR2 (0.47) | HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091410-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-09-17 | — | — | US | disclosed |
| EP-3896060-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-08-16 | — | — | EP | disclosed |
| US-20220017514-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-20 | — | — | US | disclosed |
| EP-3896060-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12091410-B2 | Heterocyclic compound | HCRTR2, HCRTR1, NTSR2 | HCRTR2 1/4885 |
| US-20220017514-A1 | HETEROCYCLIC COMPOUND | HCRTR2, HCRTR1, NTSR2 | HCRTR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.